From the Editor-in-Chief’s Desk: Are Omega-3 Fatty Acid Supplements an Effective,Safe,and Scalable Treatment for Depression in Children and Adolescents?
Restricted accessEditorialFirst published online September, 2024
From the Editor-in-Chief’s Desk: Are Omega-3 Fatty Acid Supplements an Effective,Safe,and Scalable Treatment for Depression in Children and Adolescents?
LamC, HanL, McIntyreRS, et al.Comparative efficacy of Omega-3 fatty acid with other interventions for depression in children and adolescents: A systematic review and network meta-analysis. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0017
2.
LyuN, RowanPJ, AbughoshS, et al.Trajectories and predictors for the development of clinically significant weight gain in children and adolescents prescribed second-generation antipsychotics. J Child Adolesc Psychopharmacol, 2024; 34(4):201–209; doi: 10.1089/cap.2023.0071
3.
McNamaraRK, LiW, LeiD, et al.Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial. Bipolar Disord, 2022; 24(2):161–170; doi: 10.1111/bdi.13110
4.
MendezEM, DahlsgaardKK, HjelmgrenJM, et al.What is the added benefit of combining cognitive behavioral therapy and selective serotonin reuptake inhibitors in youth with obsessive compulsive disorder? a bayesian hierarchical modeling meta-analysis. J Child Adolesc Psychopharmacol, 2023; 33(6):203–211; doi: 10.1089/cap.2023.0018
5.
MillsJA, MendezE, StrawnJR. The impact of development on antidepressant and placebo response in anxiety disorders: A bayesian hierarchical meta-analytic examination of randomized controlled trials in children, adolescents, and adults. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0016
6.
RadeckiDT, RobiesonWZ, GopalkrishnanM, et al.Safety and efficacy of levomilnacipran extended release in pediatric patients aged 7–17 years with major depressive disorder: Results of Two Phase 3, Randomized, Double-Blind Studies. J Child Adolesc Psychopharmacol, 2024; 34(5):241–250; doi: 10.1089/cap.2023.0080
7.
Valicenti-McDermottM, RivelisE, SeijoR, et al.Diagnosis of autism in school age and adolescence in an ethnically diverse population. J Child Adolesc Psychopharmacol, 2024; 34(6):275–277; doi: 10.1089/cap.2024.0004
8.
WeissMD, DaniolosPT, CoughlinK, et al.A scoping review of the intersectionality of autism and intellectual and developmental disability with social inequity on diagnosis and treatment of youth. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2023.0058
9.
WestLM, MooneySJ, ChavezL, et al.Evaluation of the safer use of antipsychotics in youth study on population level antipsychotic initiation: An interrupted time series analysis. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0007
10.
ZhangY, ZhangW, YuE. Systematic review and meta-analysis: Pharmacological and nonpharmacological interventions for disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol, 2024; 34(5):217–225; doi: 10.1089/cap.2024.0013
